Shares of other companies:
April 29, 2024 Tesla, Baidu Join Forces for Self-Driving Tech in China
April 27, 2024 Alphabet and Microsoft’s AI Investments Yield Strong Returns
April 26, 2024 Top 10 High Dividend Yield Stocks
Tesla Q1: Facing A Liquidity Crunch; Dilution Ahead?
April 29, 2024
Tesla Q1: Model 2 Could Be Their Model T
April 25, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
MNMD Stock News and Mentions of Mind Medicine (MindMed) Inc. Stocktwits
Updated: April 30, 2024 (10:17)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Mind Medicine (MindMed) Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Mind Medicine (MindMed) Inc. (MNMD).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Mind Medicine (MindMed) stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Mind Medicine (MindMed) Inc. (MNMD)
April 25, 2024 (09:37) / "Motley Fool" (by David Jagielski)
This Small-Cap Stock Is Up 140% This Year and Here's Why It Can Go Even Higher
For investors with a high level of risk tolerance, Mind Medicine could be an intriguing investment option.
In Article Trend: Somewhat-Bullish
April 19, 2024 (19:23) / "Benzinga" (by Caleb Naysmith)
Jim Cramer Slams Political Blocking Of 'LSD-Derived Antidepressants,' Citing Strong Test Data 'Showing They Worked' - ATAI Life Sciences ( NASDAQ:ATAI ) , Compass Pathways ( NASDAQ:CMPS )
Jim Cramer recently hyped up one of his guests in advance of his CNBC show "Mad Money," posting on X that people "will be very interested in MindMed for certain … LSD," and he made sure his interview did not disappoint. Mind Medicine Inc.
In Article Trend: Somewhat-Bullish
April 10, 2024 (14:56) / "Benzinga" (by Avi Kapoor)
Roblox, TAL Education And Other Big Stocks Moving Higher On Wednesday - Roblox ( NYSE:RBLX )
U.S. stocks were lower, with the Dow Jones index falling over 300 points on Wednesday. Shares of Roblox Corporation RBLX rose during Wednesday's session following reports the company has ramped up efforts to attract advertisers to its platform and made other moves to boost advertising sales.
In Article Trend: Somewhat-Bullish
April 8, 2024 (10:59) / "Zacks Commentary" (by Zacks Equity Research)
MindMed ( MNMD ) Stock Rises 154% in 3 Months: Here's Why
MindMed's (MNMD) progress with the development of its lead candidate MM120 for treating generalized anxiety disorder has been encouraging, leading the stock to rise during this time.
In Article Trend: Somewhat-Bullish
April 4, 2024 (09:18) / "Benzinga" (by Avi Kapoor)
Simulations Plus Posts Upbeat, Joins Levi Strauss, BlackBerry And Other Big Stocks Moving Higher In Thursday's Pre-Market Session - BlackBerry ( NYSE:BB ) , Simulations Plus ( NASDAQ:SLP ) , Levi Strauss ( NYSE:LEVI )
U.S. stock futures were higher this morning, with the Dow futures gaining by around 90 points on Thursday. Shares of Simulations Plus, Inc. SLP rose sharply in today's pre-market trading after the company posted better-than-expected results for its second quarter.
In Article Trend: Somewhat-Bullish
April 2, 2024 (11:30) / "Benzinga" (by Globe Newswire)
Optimi Health Receives Finished Product Test Results and Certificate Of Analysis for GMP Natural Psilocybin Extract - Optimi Health ( OTC:OPTHF )
VANCOUVER, British Columbia, April 02, 2024 ( GLOBE NEWSWIRE ) -- Optimi Health Corp.
In Article Trend: Somewhat-Bullish
March 28, 2024 (11:30) / "GlobeNewswire" (by Optimi Health Corp.)
Optimi Health Confirms Presenting Sponsorship at the 4th Annual Psychedelic Therapeutics and Drug Development Conference
Optimi Health secures Presenting Sponsorship at the highly anticipated 4th Annual Psychedelic Therapeutics and Drug Development Conference in Boston, MA.
In Article Trend: Somewhat-Bullish
March 27, 2024 (15:12) / "Money Morning" (by Chris Johnson)
MindMed's Set to Pass a Psychological Market Test
It's a little ironic ( strangely I hear Alanis Morissette singing that as I type ) that I'm talking about psychological levels with a psychedelic stock. Shares of Mind Medicine ( MNMD ) are preparing for one of the biggest moves a stock under $10 can make. The stock is setting up for a ...
In Article Trend: Neutral
March 27, 2024 (14:25) / "Benzinga" (by Lara Goldstein)
Podcast: LSD 'Deserves To Reclaim Its Spot At The Lead Of The Path For Psychedelics' Says MindMed's R. Barrow - Mind Medicine ( NASDAQ:MNMD )
Welcome to a new episode of the Benzinga Psychedelics Podcast where we're joined by Robert Barrow, CEO of Mind Medicine ( MindMed ) MNMD, which has taken the development of LSD-based therapy to new heights.
In Article Trend: Neutral
March 18, 2024 (15:23) / "Zacks Commentary" (by Kanishka Das)
Cybin ( CYBN ) Begins Phase II Study on Anxiety Drug, Stock Up
Cybin (CYBN) initiates a phase II proof-of-concept study evaluating CYB004 for the treatment of generalized anxiety disorder. The stock rises 7.2%.
In Article Trend: Neutral
March 18, 2024 (12:55) / "GlobeNewswire" (by PharmAla Biotech)
Cortexa Leads the World in First Supply of Psilocybin Under the TGA's Authorized Prescriber Scheme
PharmAla's 50:50 Joint Venture with Vitura Health Limited, Cortexa, announces it is first entity to supply Psilocybin into Authorized Prescriber Scheme ...
In Article Trend: Neutral
March 14, 2024 (12:05) / "Benzinga" (by Avi Kapoor)
Why Robinhood Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket - Robinhood Markets ( NASDAQ:HOOD )
Shares of Robinhood Markets, Inc. HOOD rose sharply in today's pre-market trading after the company reported February trading metrics. After the market close on Wednesday, Robinhood said total funded customers grew to 23.6 million at the end of February, up approximately 130,000 from January.
In Article Trend: Neutral
March 13, 2024 (15:03) / "Money Morning" (by Chris Johnson)
Three Stocks: MindMed, Tesla, and Dollar Tree
What a ride it has been for Mind Medicine ( MNMD ) investors. We saw the stock shoot through the sky last week on news that the FDA had granted "Breakthrough Therapy Designation" to one of the company's trial treatments, but then shares dropped 30% from their highs.
In Article Trend: Neutral
March 8, 2024 (15:59) / "Money Morning" (by Chris Johnson)
This is Just the Beginning of Mind Medicine
My colleague Nick Riso penned an incredibly timely article on Monday. The piece, titled, "Why The Psychedelic Boom Is All but Inevitable" discussed the coming boom of various psychedelic treatments to address a growing mental health crisis.
In Article Trend: Somewhat-Bullish
March 8, 2024 (15:46) / "Zacks Commentary" (by Zacks Equity Research)
MindMed's ( MNMD ) Anxiety Drug Gets FDA Breakthrough Therapy Tag
The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.
In Article Trend: Somewhat-Bullish
March 8, 2024 (14:46) / "Zacks Commentary" (by Zacks Equity Research)
MindMed's ( MNMD ) Anxiety Drug Gets FDA Breakthrough Therapy Tag
The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.
In Article Trend: Somewhat-Bullish
March 8, 2024 (12:00) / "Canada Newswire" (by Numinus Wellness Inc.)
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for Generalized Anxiety Disorder
Numinus Wellness Congratulates MindMed on Positive Results from Phase 2B Clinical Trials of MM120 for ... Canada ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (19:31) / "Benzinga" (by Avi Kapoor)
S&P 500 Gains 1%; Kroger Earnings Top Views - Brera Holdings ( NASDAQ:BREA ) , Avid Bioservices ( NASDAQ:CDMO )
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 250 points on Thursday. The Dow traded up 0.34% to 38,793.79 while the NASDAQ rose 1.63% to 16,292.61. The S&P 500 also rose, gaining, 1.06% to 5,158.91. Communication services shares jumped by 1.9% on ...
In Article Trend: Neutral
March 7, 2024 (18:35) / "Benzinga" (by Lara Goldstein)
MindMed Receives FDA 'Breakthrough Therapy' Designation For LSD As Anxiety Treatment, Shares Positive Results About Related Clinical Trials - Compass Pathways ( NASDAQ:CMPS ) , Mind Medicine ( NASDAQ:MNMD )
Mind Medicine ( MindMed ) MNMD announced that the FDA has granted the "breakthrough therapy" designation to its MM120 ( lysergide d-tartrate ) program for the treatment of Generalized Anxiety Disorder ( GAD ) .
In Article Trend: Neutral
March 7, 2024 (14:54) / "Benzinga" (by Adam Eckert)
What's Going On With MindMed Stock Thursday? - Mind Medicine ( NASDAQ:MNMD )
Mind Medicine Inc MNMD shares are trading higher Thursday after the company received FDA breakthrough therapy designation and announced positive study data. What Happened: MindMed announced that the FDA has granted breakthrough designation to its MM120 ( lysergide d-tartrate ) program for the ...
In Article Trend: Somewhat-Bullish
March 7, 2024 (12:00) / "CNN" (by Sandee LaMotte)
Single dose of LSD provides immediate, lasting anxiety relief, study says
Single dose of LSD provides immediate and lasting relief from anxiety, study says ...
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website